If you have been reading about peptide mapping and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-21. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | 31 amino acid residues |
| Molecular formula | C187H291N45O59 | free peptide, no counter-ion |
| Approximate mass | 4114 Da | matches theoretical value |
| Receptor target | Glucagon-like peptide-1 receptor | Gs-coupled, cyclic AMP pathway |
| Circulation half-life | About one week in humans | extended by albumin association |
Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。
该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
== Interactions == Spironolactone often increases serum potassium levels and can cause hyperkalemia, a very serious condition. Therefore, people using this medication should avoid potassium supplements and salt substitutes containing potassium. Physicians must be careful to monitor potassium levels in both males and females who are taking spironolactone as a diuretic, especially during the first 12 months of use and whenever the dosage is increased. Doctors may also recommend that some patients may be advised to limit dietary consumption of potassium-rich foods. Recent data suggest that both potassium monitoring and dietary restriction of potassium intake are unnecessary in healthy young women taking spironolactone for acne and in healthy, young, gender-diverse individuals taking spironolactone for hormone therapy. Spironolactone together with trimethoprim/sulfamethoxazole increases the likelihood of hyperkalemia, especially in the elderly. The trimethoprim portion acts to prevent potassium excretion in the distal tubule of the nephron. Spironolactone has been reported to induce the enzymes CYP3A4 and certain UDP-glucuronosyltransferases , which can result in interactions with various medications. However, metabolites of spironolactone reportedly irreversibly inhibit CYP3A4. In any case, spironolactone has been found to reduce the bioavailability of oral estradiol, which could be due to induction of estradiol metabolism via CYP3A4. Spironolactone has also been found to inhibit UGT2B7.
=== 4 May === Explosions were reported in Kyiv and Odesa in another series of Russian air attacks. Ukraine claimed to have destroyed 18 out of the 24 drones launched, plus a reconnaissance drone, with only light damage to property; the drones were marked with messages such as "For Moscow" and "For the Kremlin". According to TASS, Ukrainian drones attacked and set ablaze the Ilsky refinery near Novorossiisk. The fire was extinguished without damage after two hours. Fighting broke out between Russian and Ukrainian delegates to the Parliamentary Assembly of the Black Sea Economic Cooperation in Ankara, Turkey. Ukrainian delegates had earlier waved Ukrainian flags during a speech by a Russian delegate. Later, Oleksandr Marikovski, a Ukrainian MP, physically assaulted a Russian official after the latter seized his flag. Ukraine for the first time intercepted a Russian Kh-47M2 Kinzhal hypersonic missile, following reports from Kyiv of a powerful explosion overnight. The Ukrainian Air Force said they shot it down using the Patriot missile system protecting the capital.
Chester Fisher died in 1965 at age 84. His sons maintained leadership of the company, with Aiken becoming Chairman and Benjamin becoming president. The youngest son, James Fisher, had the title Senior Vice President. Fisher Scientific Company issued its first public stock in 1965, and that year the company had $58 million in sales and close to a million customer transactions. In 1968 Fisher shares were listed on the New York Stock Exchange. In 1965 the company introduced the Differential Thermalyzer, a differential thermal analysis instrument. It acquired Pfeiffer Glass, Inc. in 1966, a manufacturer of high accuracy volumetric pipettes. The company released the Photometric Titralyzer that year, and a Hem-alyzer in 1968. In 1968, it purchased Massachusetts-based Jarrell-Ash Company, a producer of optical instrumentation, particularly for emission and atomic absorption spectroscopy. It acquired Chicago-based Stansi Scientific Company in 1967, expanding into educational science supplies. In 1976, Fisher Scientific established an Instrument Service Division. Fisher was acquired by Morristown, New Jersey–based Allied Corporation in 1981 for $330 million. At this time Benjamin R. Fisher was Chairman of the company, having gained the position in 1975 upon Aiken's retirement. Operating as a subsidiary of Allied Corporation (and later AlliedSignal Inc., and The Henley Group), Fisher established a Biotechnology Division in 1985. In 1991, The Henley Group sold a majority interest in Fisher through a public stock offering.
== Interactions == No interactions in humans have been described. Combining racecadotril with an ACE inhibitor can theoretically increase the risk for angioedema. Racecadotril and its main metabolites neither inhibit nor induce the liver enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. They also do not induce UGT enzymes. This means that racecadotril has a low potential for pharmacokinetic interactions.
Sources: en.wikipedia.org
NASA spin-off technologies are commercial products and services which have been developed with the help of NASA, through research and development contracts, such as Small Business Innovation Research (SBIR) or STTR awards, licensing of NASA patents, use of NASA facilities, technical assistance from NASA personnel, or data from NASA research. Information on new NASA technology that may be useful to industry is available in periodical and website form in "NASA Tech Briefs", while successful examples of commercialization are reported annually in the NASA publication Spinoffs. The publication has documented more than 2,000 technologies over time. In 1979, notable science fiction author Robert A. Heinlein helped bring awareness to the spin-offs when he was asked to appear before Congress after recovering from one of the earliest known vascular bypass operations to correct a blocked artery. In his testimony, reprinted in his 1980 book Expanded Universe, Heinlein claimed that four NASA spin-off technologies made the surgery possible, and that they were only a few from a long list of NASA spin-off technologies from space development. Since 1976, the NASA Technology Transfer Program has connected NASA resources to private industry, referring to the commercial products as spin-offs. Well-known products that NASA claims as spin-offs include memory foam (originally named temper foam), freeze-dried food, firefighting equipment, emergency "space blankets", DustBusters, cochlear implants, LZR Racer swimsuits, and CMOS image sensors.
It was published by Carl Linnaeus in 1753 with Tulipa gesneriana L. as the type species. Tulipa is a genus of the lily family, Liliaceae, once one of the largest families of monocots, but which molecular phylogenetics has reduced to a monophyletic grouping with only 15 genera. Within Liliaceae, Tulipa is placed within Lilioideae, one of three subfamilies, with two tribes. Tribe Lilieae includes seven other genera in addition to Tulipa.
Cardiac effects: oxytocin and oxytocin receptors are also found in the heart in some rodents, and the hormone may play a role in the embryonal development of the heart by promoting cardiomyocyte differentiation. However, the absence of either oxytocin or its receptor in knockout mice has not been reported to produce cardiac insufficiencies. Modulation of hypothalamic-pituitary-adrenal axis activity: oxytocin, under certain circumstances, indirectly inhibits release of adrenocorticotropic hormone and cortisol and, in those situations, may be considered an antagonist of vasopressin. Preparing fetal neurons for delivery (in rats): crossing the placenta, maternal oxytocin reaches the fetal brain and induces a switch in the action of neurotransmitter GABA from excitatory to inhibitory on fetal cortical neurons. This silences the fetal brain for the period of delivery and reduces its vulnerability to hypoxic damage. Feeding: A 2012 paper suggested that oxytocin neurons in the para-ventricular hypothalamus in the brain may play a key role in suppressing appetite under normal conditions and that other hypothalamic neurons may trigger eating via inhibition of these oxytocin neurons. This population of oxytocin neurons is absent in Prader-Willi syndrome, a genetic disorder that leads to uncontrollable feeding and obesity, and may play a key role in its pathophysiology.
Sources: en.wikipedia.org
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.
The substitution at position 8 removes the site recognised by dipeptidyl peptidase-4, the enzyme that destroys the native hormone within minutes. The linked lipophilic chain then binds circulating albumin, which further limits access by degradative enzymes and reduces renal loss. Together these features lengthen the effective circulation time considerably.
It acts at the glucagon-like peptide-1 receptor, a G protein-coupled receptor that signals mainly through cyclic AMP. Activation is glucose dependent, meaning insulin release is stimulated more strongly when blood glucose is already elevated. Other tissues carrying the same receptor respond as well, which explains effects beyond glucose control.
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.